Trial reportActa diabetologica2014
Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience.
Trial report in Acta diabetologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03791567 (Expanded Access to Donislecel for Treatment Use), which is not on this map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Expanded Access to Donislecel for Treatment Use
Who cites it
47 citing papers in PubMed, 97 citations in OpenAlex.
- Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.Diabetes care · 2020Trial
- Concerns and hopes of patients with type 1 diabetes prior to islet cell transplantation: A content analysis.Journal of diabetes and its complications · 2018Trial
- Functional analysis of adrenocorticotropic-hormone-producing pituitary cells derived from human pluripotent stem cells in murine and primate models of hypopituitarism.Stem cell research & therapy · 2026Article
- Donation After Circulatory Death Islets are Comparable to Standard-of-Care Donation After Brain Death Islets: Analysis of 801 Consecutive Human Islet Isolations.Transplantation direct · 2026Article
- Gamma Irradiation of Poly(lactide-co-glycolide) Scaffolds Reduces the Mechanical Stability and Function of Islet Grafts in Diabetic Nonhuman Primates.Biotechnology and bioengineering · 2026Article
- Longitudinal monitoring of type 1 diabetes progression to disease onset.Science advances · 2026Article
- Cell Therapy for T1D Beyond BLA: Gearing Up Toward Clinical Practice.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- A Pro-Angiogenic Immunoprotective Membrane for Cell Therapies.Advanced healthcare materials · 2025Article
- The future of islet transplantation beyond the BLA approval: challenges and opportunities.Frontiers in transplantation · 2025Review
- Enhancing the Functionality of Immunoisolated Human SC-βeta Cell Clusters through Prior Resizing.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- A wireless, battery-free device enables oxygen generation and immune protection of therapeutic xenotransplants in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Type 1 Diabetes Mellitus Management and Islet Cell Therapy: A New Chapter in Patient Care.Cureus · 2023Article
- Islet transplantation-immunological challenges and current perspectives.World journal of transplantation · 2023Review
- Mesenchymal Stem Cell in Pancreatic Islet Transplantation.Biomedicines · 2023Review
- A hydrogel platform for co-delivery of immunomodulatory proteins for pancreatic islet allografts.Journal of biomedical materials research. Part A · 2022Article
- The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia · 2021Article
- Fibroblast growth factor 7 releasing particles enhance islet engraftment and improve metabolic control following islet transplantation in mice with diabetes.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- High Concentrations of Etanercept Reduce Human Islet Function and Integrity.Journal of inflammation research · 2021Article
- A Smartphone-Fluidic Digital Imaging Analysis System for Pancreatic Islet Mass Quantification.Frontiers in bioengineering and biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
This report summarizes a 5-year phase 1/2 allogeneic islet transplantation clinical trial conducted at the University of Illinois at Chicago (UIC). Ten patients were enrolled in this single center, open label, and prospective trial in which patients received 1-3 transplants. The first four subjects underwent islet transplantation with the Edmonton immunosuppressive regimen and the remaining six subjects received the UIC immunosuppressive protocol (Edmonton plus etanercept and exenatide). All 10 patients achieved insulin independence after 1-3 transplants. At 5 years of follow-up, 6 of the initial 10 patients were free of exogenous insulin. During the follow-up period, 7 of the 10 patients maintained positive C-peptide levels and a composite hypoglycemic score of 0. Most patients maintained HbA1c levels <6.0 % (42.1 mmol/mol) and a significantly improved β-score. In conclusion, this study demonstrated long-term islet graft function without using T cell depleting induction, with an encouraging outcome that includes 60 % of patients remaining insulin independent after 5 years of initial transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.